Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | KAZ954 |
Synonyms | |
Therapy Description |
KAZ954 is a monoclonal antibody targeting ectonucleoside triphosphate diphosphohydrolase (ENTPD2), which inhibits the hydrolysis of ATP to ADP and potentially induces antibody-dependent cell-mediated cytotoxicity (ADCC) and inhibition of tumor growth (Mol Cancer Ther (2023) 22 (12_Supplement): PR015). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
KAZ954 | KAZ-954|KAZ 954 | KAZ954 is a monoclonal antibody targeting ectonucleoside triphosphate diphosphohydrolase (ENTPD2), which inhibits the hydrolysis of ATP to ADP and potentially induces antibody-dependent cell-mediated cytotoxicity (ADCC) and inhibition of tumor growth (Mol Cancer Ther (2023) 22 (12_Supplement): PR015). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04237649 | Phase I | KAZ954 + Spartalizumab KAZ954 + Taminadenant KAZ954 KAZ954 + NZV930 | KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors | Terminated | USA | ITA | ESP | CAN | 4 |